Limits...
Smad1 expression in follicular lymphoma.

Go JH - J Pathol Transl Med (2015)

Bottom Line: In the reactive germinal centers, most cells were positive for Smad1.Notably, three cases expressed CD10 only, and one only expressed Bcl6.These results indicate that Smad1 is a candidate as a germinal center marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT

Background: Follicular lymphomas present with various immunohistologic patterns. The immunohistochemical markers used in the diagnosis of follicular lymphoma show variable degrees of sensitivity and specificity, and thus, additional germinal center markers are required. Smad1 has been reported to be overexpressed in follicular lymphoma, but little is known regarding the expression patterns of Smad proteins in human lymphoid tissue.

Methods: In the present study, we performed immunohistochemistry for traditional germinal center markers and for Smad1 in human reactive lymphoid and follicular lymphoma tissues to investigate Smad1's usefulness in the diagnosis of follicular lymphoma.

Results: In the reactive germinal centers, most cells were positive for Smad1. Among the 27 follicular lymphoma cases, 17 of 21 (80%) were Smad1 positive, 17 of 27 (63%) were positive for CD10, and 23 of 27 (85%) were positive for Bcl6. Notably, three cases expressed CD10 only, and one only expressed Bcl6. All these cases were grade 3 tumors and showed follicular and diffuse growth patterns.

Conclusions: These results indicate that Smad1 is a candidate as a germinal center marker. Furthermore, they suggest that the Smad signaling pathway might be involved in follicular lymphoma.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical pattern of follicular lymphoma. The tumor cells are positive for Smad1 (A), CD10 (B), and Bcl6 (C).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4440936&req=5

f2-jptm-49-3-243: Immunohistochemical pattern of follicular lymphoma. The tumor cells are positive for Smad1 (A), CD10 (B), and Bcl6 (C).

Mentions: In reactive GCs, most cells (centrocytes and centroblasts) were positive for Smad1. No other cells expressed Smad1, with the exception of scattered plasma cells, which were more strongly positive than the GC cells (Fig. 1). Smad1 immunostaining was not performed in six cases of FLs because of a shortage of Smad1 antibody. Of the tested FL cases, 17 of 21 (80%) were Smad1+ (Fig. 2A). When we tested common GC markers, 17 of 27 (63%) were positive for CD10 (Fig. 2B) and 23 of 27 (85%) were positive for Bcl6 (Table 2, Fig. 2C). Of the 21 cases immunostained for all three antibodies, all of the grade 1 and 2 tumors were positive for Smad1, CD10, and Bcl6. For the 15 grade 3 tumors, three were positive for all three markers, eight co-expressed Smad1 and Bcl6, three expressed CD10 only and one expressed Bcl6 only (Table 3). Most tumors with a follicular growth pattern were positive for Smad1, CD10, and Bcl6 (9 of 11, 82%), and the remaining were positive for Smad1 and Bcl6 (n=2). However, of the nine tumors with a follicular and diffuse pattern, five co-expressed Smad1 and Bcl6, three expressed CD10 only, and one expressed Bcl6 only. The one case with a focally follicular pattern was positive for Smad1 and Bcl6 but was negative for CD10 (Table 4).


Smad1 expression in follicular lymphoma.

Go JH - J Pathol Transl Med (2015)

Immunohistochemical pattern of follicular lymphoma. The tumor cells are positive for Smad1 (A), CD10 (B), and Bcl6 (C).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4440936&req=5

f2-jptm-49-3-243: Immunohistochemical pattern of follicular lymphoma. The tumor cells are positive for Smad1 (A), CD10 (B), and Bcl6 (C).
Mentions: In reactive GCs, most cells (centrocytes and centroblasts) were positive for Smad1. No other cells expressed Smad1, with the exception of scattered plasma cells, which were more strongly positive than the GC cells (Fig. 1). Smad1 immunostaining was not performed in six cases of FLs because of a shortage of Smad1 antibody. Of the tested FL cases, 17 of 21 (80%) were Smad1+ (Fig. 2A). When we tested common GC markers, 17 of 27 (63%) were positive for CD10 (Fig. 2B) and 23 of 27 (85%) were positive for Bcl6 (Table 2, Fig. 2C). Of the 21 cases immunostained for all three antibodies, all of the grade 1 and 2 tumors were positive for Smad1, CD10, and Bcl6. For the 15 grade 3 tumors, three were positive for all three markers, eight co-expressed Smad1 and Bcl6, three expressed CD10 only and one expressed Bcl6 only (Table 3). Most tumors with a follicular growth pattern were positive for Smad1, CD10, and Bcl6 (9 of 11, 82%), and the remaining were positive for Smad1 and Bcl6 (n=2). However, of the nine tumors with a follicular and diffuse pattern, five co-expressed Smad1 and Bcl6, three expressed CD10 only, and one expressed Bcl6 only. The one case with a focally follicular pattern was positive for Smad1 and Bcl6 but was negative for CD10 (Table 4).

Bottom Line: In the reactive germinal centers, most cells were positive for Smad1.Notably, three cases expressed CD10 only, and one only expressed Bcl6.These results indicate that Smad1 is a candidate as a germinal center marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT

Background: Follicular lymphomas present with various immunohistologic patterns. The immunohistochemical markers used in the diagnosis of follicular lymphoma show variable degrees of sensitivity and specificity, and thus, additional germinal center markers are required. Smad1 has been reported to be overexpressed in follicular lymphoma, but little is known regarding the expression patterns of Smad proteins in human lymphoid tissue.

Methods: In the present study, we performed immunohistochemistry for traditional germinal center markers and for Smad1 in human reactive lymphoid and follicular lymphoma tissues to investigate Smad1's usefulness in the diagnosis of follicular lymphoma.

Results: In the reactive germinal centers, most cells were positive for Smad1. Among the 27 follicular lymphoma cases, 17 of 21 (80%) were Smad1 positive, 17 of 27 (63%) were positive for CD10, and 23 of 27 (85%) were positive for Bcl6. Notably, three cases expressed CD10 only, and one only expressed Bcl6. All these cases were grade 3 tumors and showed follicular and diffuse growth patterns.

Conclusions: These results indicate that Smad1 is a candidate as a germinal center marker. Furthermore, they suggest that the Smad signaling pathway might be involved in follicular lymphoma.

No MeSH data available.


Related in: MedlinePlus